Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Dini

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology Practical & Conceptual|February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2026
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativaGeorgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week resultsBianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology Practical & Conceptual|February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2026
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativaGeorgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week resultsBianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 19